Analyzing Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Atara Biotherapeutics and Yarrow Bioscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1	1	1	1	2.50
Yarrow Bioscience	1	0	2	0	2.33

Atara Biotherapeutics presently has a consensus target price of $9.50, indicating a potential upside of 6.38%. Yarrow Bioscience has a consensus target price of $58.00, indicating a potential upside of 102.23%. Given Yarrow Bioscience’s higher probable upside, analysts clearly believe Yarrow Bioscience is more favorable than Atara Biotherapeutics.

Volatility & Risk

Atara Biotherapeutics has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500. Comparatively, Yarrow Bioscience has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Profitability

This table compares Atara Biotherapeutics and Yarrow Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Valuation and Earnings

This table compares Atara Biotherapeutics and Yarrow Bioscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77 million	0.74	$32.69 million	($1.18)	-7.57
Yarrow Bioscience	$570,000.00	134.34	-$26.48 million	($14.64)	-1.96

Atara Biotherapeutics has higher revenue and earnings than Yarrow Bioscience. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Atara Biotherapeutics beats Yarrow Bioscience on 9 of the 15 factors compared between the two stocks.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.